Antibody-Mediated Rejection: Addressing the Underlying Issues for Improved Patient Outcomes
Program Overview
The goal of this activity is to provide education about AMR treatment principles, guidelines, and emerging therapies. Faculty will discuss the genesis of alloantibody production and how it contributes to graft loss, as well as unmet needs in AMR therapies. An experienced patient with AMR provides insights for transplant clinicians to consider when treating their patients with AMR.
This activity is intended for clinicians actively engaged in managing antibody-mediated rejection (AMR) in transplant patients, including transplant physician, surgeons, NPs, and PAs with an interest in transplant
Educational Objectives
Upon completion of this activity, participants should be better able to:
Summarize the pathophysiology of antibody-mediated rejection (AMR), including the role of the complement system and cytokine pathways in disease pathogenesis
Evaluate the efficacy and safety data supporting existing and emerging treatment options for AMR, including anti-complement and anti-cytokine strategies
Select appropriate treatments for patients with AMR to improve allograft survival
Activity Faculty
Robert A. Montgomery, MD, DPhil, FACS (Chair)
Professor of Surgery
Director, NYU Langone Transplant Institute
New York, NY
Arjang Djamali, MD, MS, FASN
Professor, Medicine and Surgery Head, Division of Nephrology
Department of Medicine
University of Wisconsin
School of Medicine and Public Health
Madison, WI
Stanley C. Jordan, MD, FASN, FAST
Director, Nephrology & Transplant Immunology Medical Director, Kidney Transplant Program
Cedars-Sinai Medical Center Professor, Pediatrics & Medicine
David Geffen School of Medicine at UCLA
Los Angeles, CA